维立志博成立于2012年，是一家处于临床阶段的生物科技公司，致力于创新疗法的发现、开发及商业化，重点解决PD-1/PD-L1抗体为代表的现有疗法不能治疗的疾病，以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。
PD-L1与 4-1BB双靶向双特异性抗
成功建立涵盖抗体发现及工程、体内及体外疗效评估以及成药性评估的综合研发能力，拥有高效的药物开发流程
*根据弗若斯特沙利文的资料，显著快于行业5-6年的平均水平
'%20fill='%23868686'%20fill-rule='nonzero'%3e%3cg%20id='icon_qx'%20transform='translate(343,%20613)'%3e%3cpath%20d='M14.7073469,13.2954501%20L8.91225312,7.50026721%20L14.7073246,1.70450489%20C14.8962609,1.51559088%2015.0001781,1.26441124%2015,0.997208354%20C14.9998215,0.730807741%2014.8960603,0.480742374%2014.7078594,0.293076342%20C14.5193688,0.104095468%2014.2690361,0.000155995232%2014.0025909,0%20C13.7350091,0%2013.4840969,0.103917194%2013.2953612,0.292586056%20L7.50042344,6.0875461%20L1.70450512,0.292586078%20C1.51583626,0.103917216%201.26512461,0%200.998545704,0%20C0.731989095,0%200.481277447,0.103894915%200.292630864,0.292541498%20C0.104028861,0.480630937%200.000178524818,0.730807741%200,0.997208354%20C-0.000178045047,1.26441124%200.103739127,1.51559088%200.292630864,1.70448261%20L6.0885046,7.50024494%20L0.292608586,13.2954724%20C0.103917423,13.4841413%200,13.7348083%200,14.0014095%20C0,14.2679661%200.103939724,14.5187%200.292630886,14.7073912%20C0.481277469,14.8960601%200.731966816,14.9999327%200.998523446,14.9999327%20C1.26510236,14.9999327%201.51583628,14.8960378%201.70448287,14.7073912%20L7.50033432,8.91227517%20L13.2954726,14.7073912%20C13.4841415,14.8960601%2013.735076,14.9999327%2014.0020115,14.9999327%20C14.2691252,14.9997544%2014.5192129,14.8960155%2014.7069458,14.7078369%20C15.0964959,14.3182422%2015.0966073,13.6847106%2014.7073469,13.2954501%20Z'%20id='路径'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)